← Leaderboards
Dean L Kellogg
University Of Texas Hlth Sci Ctr San Ant
$3,465,112
Attributed
$5,320,486
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,320,486 · 9
VA$0 · 1
By mechanism
U01$2,296,638 · 1
R01$1,994,811 · 1
R21$825,161 · 2
R03$125,370 · 1
M01$78,506 · 4
I21$0 · 1
Top collaborators
- Ellen Kraig4 shared
- Brett C Ginsburg2 shared
- John M Johnson1 shared
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Jeffrey W Kiel$3,253,745
- Andrea Giuffrida$4,173,873
- Ralph A Defronzo$27,122,787
- John M Johnson$2,155,193
Others in their field
Top investigators on “Microdialysis”
- Leonard L Howell · Emory University$16,286,809
- Jerome M Siegel · University Of California Los Angeles$14,997,651
- William Joseph McBride · Indiana Univ-Purdue Univ At Indianapolis$12,891,522
- Klaus A Miczek · Tufts University Medford$12,529,122
- David M Holtzman · Washington University$11,460,215
- Sara R Jones · Wake Forest University Health Sciences$10,628,023
Research focus
MicrodialysisSiteSkinPersonsHuman SubjectVasoactive Intestinal PeptideMonitorCyclic GmpBradykininCyclic AmpResponseNitric OxideForearmPharmaceutical PreparationsBlood FlowLaser-Doppler FlowmetryClinical ResearchVasodilationBlood VesselsCutaneousIn VivoInterstitialFutureMeasurement
Grant awards (23)
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,232,321
U01 · FY2025 · AG
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,064,317
U01 · FY2024 · AG
Elucidating sympathetic vasoconstrictor mechanisms of autonomic dysreflexia in persons with spinal cord injury$0
I21 · FY2022 · VA · contact PI
An innovative proof-of-concept approach to identify age-modulating drugs capable of reversing inflammation and re-setting the epigenetic clock$193,438
R21 · FY2021 · AG
Elucidating sympathetic vasoconstrictor mechanisms of autonomic dysreflexia in persons with spinal cord injury$0
I21 · FY2021 · VA · contact PI
An innovative proof-of-concept approach to identify age-modulating drugs capable of reversing inflammation and re-setting the epigenetic clock$231,000
R21 · FY2020 · AG
TRPV1 mediation of local vasoconstrictor reflexes in spinal cord injured humans$62,370
R03 · FY2014 · NS · contact PI
Translational Model Development: Rapamycin, Aging, and Endothelial Dysfunction$176,597
R21 · FY2013 · AG · contact PI
TRPV1 mediation of local vasoconstrictor reflexes in spinal cord injured humans$63,000
R03 · FY2013 · NS · contact PI
Translational Model Development: Rapamycin, Aging, and Endothelial Dysfunction$224,126
R21 · FY2012 · AG · contact PI
Mechanisms of Cutaneous Active Vasodilation$265,610
R01 · FY2008 · HL · contact PI
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION IN HUMANS$260
M01 · FY2008 · RR · contact PI
Mechanisms of Cutaneous Active Vasodilation$265,610
R01 · FY2007 · HL · contact PI
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION IN HUMANS$25,351
M01 · FY2007 · RR · contact PI
Mechanisms of Cutaneous Active Vasodilation$273,543
R01 · FY2006 · HL · contact PI
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION IN HUMANS$18,286
M01 · FY2006 · RR · contact PI
Mechanisms of Cutaneous Active Vasodilation$280,125
R01 · FY2005 · HL
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION IN HUMANS$15,815
M01 · FY2005 · RR
Mechanisms of Cutaneous Active Vasodilation in Humans$18,794
M01 · FY2004 · RR
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION$213,500
R01 · FY2003 · HL
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION$213,500
R01 · FY2002 · HL
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION$213,500
R01 · FY2001 · HL
MECHANISMS OF CUTANEOUS ACTIVE VASODILATION$269,423
R01 · FY2000 · HL